Zenas BioPharma, Inc. Operating Cash Flow
Zenas BioPharma, Inc. (ZBIO) reported Operating Cash Flow of -$132.43 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-13
- Zenas BioPharma, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$57.24M.
- Zenas BioPharma, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$75.20M.
- Zenas BioPharma, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$52.41M.
- Zenas BioPharma, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$41.13M.
- Zenas BioPharma, Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$172.33M.
- Zenas BioPharma, Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$119.67M.
- Zenas BioPharma, Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$30.53M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$57.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$132.43M 10-Q · filed 2026-08-13 | -$184.85M derived: sum of 3 quarters · filed 2026-08-13 | -$225.97M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$75.20M 10-Q · filed 2026-05-13 | -$127.61M derived: sum of 2 quarters · filed 2026-05-13 | -$168.74M derived: sum of 3 quarters · filed 2026-05-13 | -$210.48M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | -$52.41M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | -$93.54M derived: sum of 2 quarters · filed 2026-03-16 | -$135.28M derived: sum of 3 quarters · filed 2026-08-13 | -$172.33M 10-K · filed 2026-03-16 |
| 2025-09-30 | -$41.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$82.87M derived: sum of 2 quarters · filed 2026-08-13 | -$119.92M 10-Q · filed 2025-11-12 | -$158.47M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$41.74M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$78.79M 10-Q · filed 2026-08-13 | -$117.35M derived: sum of 3 quarters · filed 2026-08-13 | -$148.41M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$37.05M 10-Q · filed 2026-05-13 | -$75.61M derived: sum of 2 quarters · filed 2026-05-13 | -$106.66M derived: sum of 3 quarters · filed 2026-05-13 | -$137.62M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | -$38.55M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | -$69.61M derived: sum of 2 quarters · filed 2026-03-16 | -$100.57M derived: sum of 3 quarters · filed 2026-03-16 | -$119.67M 10-K · filed 2026-03-16 |
| 2024-09-30 | -$31.06M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$62.02M derived: sum of 2 quarters · filed 2025-11-12 | -$81.12M 10-Q · filed 2025-11-12 | -$96.52M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$30.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$50.06M 10-Q · filed 2025-08-12 | -$65.46M derived: sum of 3 quarters · filed 2025-08-12 | |
| 2024-03-31 | -$19.10M 10-Q · filed 2025-05-15 | -$34.50M derived: sum of 2 quarters · filed 2025-05-15 | ||
| 2023-12-31 | -$15.40M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | -$30.53M 10-K · filed 2025-03-11 | ||
| 2023-09-30 | -$15.13M 10-Q · filed 2024-11-12 |